| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.pdindia.com | |
| Market Cap | 10.11 Cr. | |
| Enterprise Value(EV) | 116.34 Cr. | 2022-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -25.61 | Trailing Twelve Months Ending 2022-03 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2022-03 |
| Industry PE | 41.74 | Trailing Twelve Months Ending 2022-03 |
| Book Value / Share | -278.81 | Trailing Twelve Months Ending 2022-03 |
| Price to Book Value | -0.01 | Calculated using Price: 3.39 |
| Dividend Yield | 0.00 | Period Ending 2021-03 |
| No. of Shares Subscribed | 2.98 Cr. | 29,816,300 Shares |
| FaceValue | 10 | |
| About Parenteral Drugs (India) Ltd. | ||
| Established in the year 1983, Parenteral Drugs has dedicated itself to the manufacturing of the best quality vital life saving drug at the lowest possible cost. Over the years, its path breaking innovation has led not only to lower costs but better quality as well because PDPL firmly believes that better quality dose not necessarily mean higher price, it can also be achieved by indigenous techniques and innovative technologies. | ||
No Deliveries found
| 1 Day |
|
|
| 1 Week |
|
|
| 1 Month |
|
|
| 3 Month |
|
|
| 6 Month |
|
|
| 1 Year |
|
-17.72% |
| 2 Year |
|
-28.48% |
| 5 Year |
|
-52.65% |
| 10 Year |
|
-89.12% |
| 9 years | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | |
| Return on Equity (%) | -44.85 | -23.61 | -46.67 | -152.43 | 0 | 0 | 0 | 0 | 0 | |
| Return on Capital Employed (%) | -5.15 | 1.9 | -2.29 | -8.13 | -6.91 | -5.55 | -35.07 | -52.31 | 0 | |
| Return on Assets (%) | -12.8 | -5.44 | -8.41 | -12.6 | -12.16 | -13.17 | -23.45 | -26.72 | -29.65 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03* Rs. Cr. |
| Shh. Funds | 246 | 202 | 127 | 325 | -17 | -136 | -447 | -561 | -683 | -824 | |
| Non Curr. Liab. | 427 | 456 | 427 | 440 | 462 | 370 | 4 | -26 | -59 | -91 | |
| Curr. Liab. | 162 | 166 | 230 | 300 | 428 | 593 | 878 | 1,006 | 1,144 | 1,201 | |
| Minority Int. | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Equity & Liab. | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 | |
| Non Curr. Assets | 629 | 619 | 549 | 902 | 750 | 727 | 368 | 351 | 334 | 219 | |
| Curr. Assets | 192 | 200 | 235 | 163 | 122 | 99 | 67 | 67 | 68 | 67 | |
| Misc. Exp. not W/O | 14 | 5 | 1 | 1 | |||||||
| Total Assets | 835 | 825 | 785 | 1,066 | 872 | 827 | 435 | 419 | 402 | 286 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. TTM |
| Net Sales | 327 | 274 | 263 | 260 | 230 | 224 | 32 | 32 | 12 | 9 | |
| Other Income | 0 | 61 | 1 | 2 | 6 | 2 | 1 | 0 | 0 | 0 | |
| Total Income | 328 | 334 | 264 | 262 | 236 | 226 | 33 | 32 | 12 | 9 | |
| Total Expenditure | -341 | -350 | -248 | -296 | -252 | -225 | -50 | -47 | -24 | -24 | |
| PBIDT | -14 | -15 | 15 | -34 | -17 | 0 | -16 | -14 | -12 | -16 | |
| Interest | -56 | -60 | -70 | -70 | -86 | -98 | -96 | -110 | -125 | -106 | |
| Depreciation | -23 | -19 | -31 | -23 | -25 | -24 | -69 | -17 | -17 | -40 | |
| Taxation | -15 | 1 | 19 | 10 | 10 | 10 | 33 | 28 | 33 | 33 | |
| Exceptional Items | 47 | 0 | -1 | 0 | 52 | ||||||
| PAT | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -108 | -45 | -68 | -117 | -118 | -112 | -148 | -114 | -122 | -76 | |
| Adjusted EPS | -42 | -15 | -23 | -39 | -40 | -38 | -50 | -38 | -41 | -26 |
| Particulars | 10 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. |
| Cash Fr. Operatn. | 20 | -168 | -60 | 2 | 58 | 134 | 167 | 477 | 112 | 125 | |
| Cash Fr. Inv. | -147 | -18 | 33 | 3 | -110 | -1 | -1 | 97 | 0 | 0 | |
| Cash Fr. Finan. | 133 | 182 | 25 | -10 | 54 | -134 | -167 | -574 | -112 | -125 | |
| Net Change | 5 | -3 | -2 | -5 | 1 | 0 | 0 | 0 | 0 | 0 | |
| Cash & Cash Eqvt | 13 | 11 | 8 | 3 | 5 | 0 | 0 | 0 | 0 | 0 |
|
Thu, 25 Apr 2024
Corporate Insolvency Resolution Process (CIRP)-Outcome of meeting of Committee of Creditors We would like to inform that the Tenth meeting of Committee of Creditors (CoC) pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations of the Company was held on Wednesday 24th April 2024 at 3:00 P.M. |
|
Thu, 25 Apr 2024
Corporate Insolvency Resolution Process (CIRP)-Intimation of meeting of Committee of Creditors Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (LODR) and in accordance with the requirements of sub-clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we would like to inform that the 10th meeting of Committee of Creditors (CoC) of the Company Scheduled for Wednesday 24th April 2024 at 03:00 PM. |
|
Tue, 02 Apr 2024
Approval Of Resolution Plan By COC Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 (Listing Regulations) and in accordance with the requirements of sub- clause 16(g) of Clause A of Part A of Schedule III of Listing Regulations we wish to inform you that the Committee of Creditors (CoC) of Parenteral Drugs (India) Limited the Corporate Debtor in its 9th meeting approved the resolution plan of the Corporate Debtor. Further the resolution plan is being filed with NCLT Ahmedabad for approval |
|
No Scans Found |
